Skip to main content
Top
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Case report

Alveolar Rhabdomyosarcoma of the foot metastasizing to the Iris: report of a rare case

Authors: Ido Didi Fabian, G. Darius Hildebrand, Shaun Wilson, Tina Foord, Mandeep S. Sagoo

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Intraocular iris rhabdomyosarcoma is extremely rare, and in the 3 cases reported to date occurred as the primary site of tumour growth. We report a case of rhabdomyosarcoma of the foot metastasizing to the iris.

Case presentation

An 18-year-old white female was referred to the London Ocular Oncology Service for management of a metastatic rhabdomyosarcomatous deposit in the iris, a metastasis from alveolar rhabdomyosarcoma of the foot. She was diagnosed nearly 2 years earlier with the primary sarcoma with extensive systemic spread and treated by resection of the foot lesion and chemotherapy, and achieved a partial remission. The left iris deposit was noted while she was receiving systemic chemotherapy, heralding a relapse. However, anterior uveitis and raised intraocular pressure developed and she was referred to our service for further management. A left iris secondary rhabdomyosarcoma deposit was noticed and in addition a lacrimal gland mass, as indicated by ultrasound B scan of the eye and orbit. The patient was treated with external beam radiotherapy to the globe and orbit, but died 2 months after treatment completion.

Conclusion

Rhabdomyosarcoma of the iris is very rare and was previously documented only as a primary malignancy in this location. We report that secondary spread to the iris can also occur, in this case as the first sign of widely disseminated systemic relapse.
Literature
1.
go back to reference Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R. The third intergroup Rhabdomyosarcoma study. J Clin Oncol. 1995;13:610–30. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R. The third intergroup Rhabdomyosarcoma study. J Clin Oncol. 1995;13:610–30.
2.
go back to reference Shields JA, Shields CL. Rhabdomyosarcoma: review for the ophthalmologist. Surv Ophthalmol. 2003;48:39–57.CrossRef Shields JA, Shields CL. Rhabdomyosarcoma: review for the ophthalmologist. Surv Ophthalmol. 2003;48:39–57.CrossRef
3.
go back to reference Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE. Survey of 520 eyes with uveal metastases. Ophthalmology. 1997;104:1265–76.CrossRef Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE. Survey of 520 eyes with uveal metastases. Ophthalmology. 1997;104:1265–76.CrossRef
4.
go back to reference Konstantinidis L, Rospond-Kubiak I, Zeolite I, Heimann H, Groenewald C, Coupland SE, Damato B. Management of patients with uveal metastases at the Liverpool Ocular Oncology Centre. Br J Ophthalmol. 2014;98:92–98.CrossRef Konstantinidis L, Rospond-Kubiak I, Zeolite I, Heimann H, Groenewald C, Coupland SE, Damato B. Management of patients with uveal metastases at the Liverpool Ocular Oncology Centre. Br J Ophthalmol. 2014;98:92–98.CrossRef
5.
go back to reference Shields CL, Kaliki S, Crabtree GS, Peshtani A, Morton S, Anand RA, Coco G, Shields JA. Iris metastasis from systemic cancer in 104 patients: the 2014 Jerry A. Shields Lecture. Cornea. 2015;34:42–8.CrossRef Shields CL, Kaliki S, Crabtree GS, Peshtani A, Morton S, Anand RA, Coco G, Shields JA. Iris metastasis from systemic cancer in 104 patients: the 2014 Jerry A. Shields Lecture. Cornea. 2015;34:42–8.CrossRef
6.
go back to reference Woyke S, Chwirot R. Rhabdomyosarcoma of the iris. Report of the first recorded case. Br J Ophthalmol. 1972;56:60–4.CrossRef Woyke S, Chwirot R. Rhabdomyosarcoma of the iris. Report of the first recorded case. Br J Ophthalmol. 1972;56:60–4.CrossRef
7.
go back to reference Font RL, Zimmerman LE. Electron microscopic verification of primary rhabdomyosarcoma of the iris. Am J Ophthalmol. 1972;74:110–7.CrossRef Font RL, Zimmerman LE. Electron microscopic verification of primary rhabdomyosarcoma of the iris. Am J Ophthalmol. 1972;74:110–7.CrossRef
8.
go back to reference Elsas FJ, Mroczek EC, Kelly DR, Specht CS. Primary rhabdomyosarcoma of the iris. Arch Ophthalmol (Chicago, Ill 1960). 1991;109:982–4.CrossRef Elsas FJ, Mroczek EC, Kelly DR, Specht CS. Primary rhabdomyosarcoma of the iris. Arch Ophthalmol (Chicago, Ill 1960). 1991;109:982–4.CrossRef
9.
go back to reference Kodet R, Newton WA, Hamoudi AB, Asmar L, Wharam MD, Maurer HM. Orbital rhabdomyosarcomas and related tumors in childhood: relationship of morphology to prognosis--an Intergroup Rhabdomyosarcoma study. Med Pediatr Oncol. 1997;29:51–60.CrossRef Kodet R, Newton WA, Hamoudi AB, Asmar L, Wharam MD, Maurer HM. Orbital rhabdomyosarcomas and related tumors in childhood: relationship of morphology to prognosis--an Intergroup Rhabdomyosarcoma study. Med Pediatr Oncol. 1997;29:51–60.CrossRef
10.
go back to reference Shields CL, Shields JA, Honavar SG, Demirci H. Clinical spectrum of primary ophthalmic rhabdomyosarcoma. Ophthalmology. 2001;108:2284–92.CrossRef Shields CL, Shields JA, Honavar SG, Demirci H. Clinical spectrum of primary ophthalmic rhabdomyosarcoma. Ophthalmology. 2001;108:2284–92.CrossRef
Metadata
Title
Alveolar Rhabdomyosarcoma of the foot metastasizing to the Iris: report of a rare case
Authors
Ido Didi Fabian
G. Darius Hildebrand
Shaun Wilson
Tina Foord
Mandeep S. Sagoo
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2496-6

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine